Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer

Rhea-AI Summary

Alto Neuroscience (NYSE: ANRO) has appointed Michael Hanley as its new Chief Operating Officer (COO). Hanley brings over 25 years of expertise in the life sciences industry, particularly in neuropsychiatric conditions like major depressive disorder and schizophrenia. His role will involve new product planning, portfolio strategy, and cross-functional leadership to enhance Alto's clinical-stage programs and biomarker platform. Hanley's extensive background includes leadership positions at Aeglea BioTherapeutics and Horizon Therapeutics. He holds a Bachelor of Business Administration from the University of Notre Dame and an MBA from Kellogg School of Management.

Positive

• Michael Hanley brings over 25 years of experience in product development and commercialization in the life sciences industry.
• Hanley has expertise in neuropsychiatric indications, beneficial for Alto's focus on CNS/neuroscience.
• Hanley’s prior roles include Chief Commercial Officer and Chief Business Officer at Aeglea BioTherapeutics, and General Manager at Horizon Therapeutics.
• Hanley's experience in managing important drugs like TRINTELLIX and ABILIFY MAINTENA, and preparing for the launch of REXULTI.
• Hanley’s leadership is expected to maximize the impact of Alto’s clinical-stage programs and biomarker platform.
• His educational background includes a Bachelor of Business Administration from the University of Notre Dame and an MBA from Kellogg School of Management.

Negative

• The press release does not provide specific details on how Hanley’s appointment will immediately impact financial performance or stock prices.
• There is no mention of any immediate new product launches or revenue-generating activities resulting from this appointment.
• Potential risks include the broad and ambitious goals stated without concrete timelines or measures of success.

– Mr. Hanley brings over two decades of leadership experience in product development and commercialization across a wide range of neuropsychiatric indications, including major depressive disorder and schizophrenia –

LOS ALTOS, Calif.--(BUSINESS WIRE)-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced the expansion of the Company’s leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies. As Alto’s COO, Mike will be responsible for new product planning, portfolio strategy, and cross-functional leadership to maximize the impact of the Company’s clinical-stage programs and biomarker platform.

“Mike has dedicated his career to leading the product life cycle for companies in CNS and psychiatry, from early-stage planning and portfolio strategy through launch and brand management,” said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto. “His expertise will be instrumental as we advance into late-stage clinical development and execute on our mission to bring targeted treatments to those in need. At Alto we aim to develop each of our programs based on sound scientific, strategic, and commercial considerations; we believe adding Mike to the team at this juncture will further our ability to do this across our broad pipeline.”

Prior to joining Alto, Mr. Hanley served as chief commercial officer and chief business officer at Aeglea BioTherapeutics. Previously, he was the general manager at Horizon Therapeutics and head of U.S. sales for Lundbeck’s psychiatry business unit, where he was responsible for managing TRINTELLIX (vortioxetine), ABILIFY MAINTENA (aripiprazole), and preparing for the launch of REXULTI (brexpiprazole). Throughout his career, Mr. Hanley has worked in, and held leadership roles across, various therapeutic areas including major depressive disorder, schizophrenia, sleep disorders, epilepsy, Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Mr. Hanley received a Bachelor of Business Administration in Marketing from the University of Notre Dame and a Master of Business Administration from the Kellogg School of Management at Northwestern University.

“Alto is a mission-driven company dedicated to transforming mental health treatments, and I am eager to join a team that has a strong scientific acumen and proven track record in the field,” added Mr. Hanley. “I look forward to leveraging my knowledge in CNS and operational experience to maximize the potential of our precision psychiatry platform and help advance our pipeline toward a number of important near-term clinical data readouts.”

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240521805369/en/

Investor Contact

Nick Smith

investors@altoneuroscience.com

Media Contact

Jordann Merkert

media@altoneuroscience.com

Source: Alto Neuroscience, Inc.

FAQ

What role will Michael Hanley play at Alto Neuroscience?

Michael Hanley has been appointed as Chief Operating Officer (COO) and will be responsible for new product planning, portfolio strategy, and cross-functional leadership.

What experience does Michael Hanley bring to Alto Neuroscience?

Michael Hanley brings over 25 years of experience in the life sciences industry, particularly in product development and commercialization for neuropsychiatric conditions.

What are Michael Hanley's previous roles before joining Alto Neuroscience?

Prior to joining Alto, Hanley served as Chief Commercial Officer and Chief Business Officer at Aeglea BioTherapeutics, and was General Manager at Horizon Therapeutics.

What educational background does Michael Hanley have?

Michael Hanley holds a Bachelor of Business Administration from the University of Notre Dame and an MBA from Kellogg School of Management at Northwestern University.

What impact could Michael Hanley’s appointment have on Alto Neuroscience's stock (ANRO)?

While specific immediate financial impacts are not detailed, Hanley's extensive experience and leadership could potentially enhance Alto's clinical-stage programs, which may positively influence stock performance over time.